isoxazoles has been researched along with hydroxyproline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JQ; Li, J; Xu, SY; Yao, HW | 1 |
| Ohashi, T; Yamamoto, T | 1 |
2 other study(ies) available for isoxazoles and hydroxyproline
| Article | Year |
|---|---|
Inhibitory effect of leflunomide on hepatic fibrosis induced by CCl4 in rats.
Topics: Adjuvants, Immunologic; Alanine Transaminase; Animals; Aspartate Aminotransferases; Carbon Tetrachloride Poisoning; Collagen Type III; Hydroxyproline; Isoxazoles; Leflunomide; Liver; Liver Cirrhosis, Experimental; Male; NF-kappa B; Nitric Oxide; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
Topics: Animals; Bleomycin; Cell Count; Chemokine CCL3; Collagen Type I; Connective Tissue Growth Factor; Disease Models, Animal; Female; Fibrosis; Hydroxyproline; Interferon-gamma; Isoxazoles; Lung; Mast Cells; Mice; Propionates; Receptors, Lysophosphatidic Acid; RNA, Messenger; Scleroderma, Systemic; Skin; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1 | 2015 |